A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Completed · Phase 3 · NCT05108922
Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease
At a glance
- Research payments reported, 2025
- $8,540
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 148
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Donanemab (drug), Aducanumab (drug)
- Dates
- Started 2021-11-16; completion 2023-09-19
- Results posted
- Yes
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
From ClinicalTrials.gov, last updated 2024-11-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $8,540 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rekha Gandhi, MD Neurology · Winter Park, FL
- Donald S. Marks, M.D. Neurology · Plymouth, MA
- Sanjiv K. Sharma, M.D. Internal Medicine · Toms River, NJ
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Advanced Memory Research Institute of Nj PC $4,500
- Headlands Eastern Ma LLC $3,920
- Conquest Research LLC $120
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.